预约演示
更新于：2025-05-31
Montelukast sodium
孟鲁司特钠
更新于：2025-05-31
概要
基本信息
简介Montelukast sodium，商业名称为SINGULAIR®，是一种CysLT拮抗剂药物，用于治疗哮喘，运动诱发的支气管痉挛（EIB）和过敏性鼻炎。这种药物于1997年在墨西哥获得首次批准，并已广泛用于全球哮喘和过敏性鼻炎的管理。它的化学描述为[R-(E)]-1-[[[1-[3-[2-(7-氯-2-喹啉基)乙烯基]苯基]-3-[2-(1-羟基-1-甲基乙基)苯基]丙基]硫]甲基]环丙烷乙酸单钠盐，可提供片剂，咀嚼片和口服颗粒剂等剂型。 |
药物类型 小分子化药 |
别名 Montelukast、Montelukast sodium (JP17/USP)、Montelukast Sodium Oral Granules + [14] |
靶点 |
作用方式 拮抗剂 |
作用机制 CysLT拮抗剂(半胱氨酰白三烯受体拮抗剂) |
最高研发阶段批准上市 |
首次获批日期 美国 (1998-02-20), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C35H36ClNNaO3S |
InChIKeyZMFQNQCXWQXCFO-HKHDRNBDSA-N |
CAS号151767-02-1 |
关联
549
项与 孟鲁司特钠 相关的临床试验NCT03277170
Pragmatic RCT of High-dose Oral Montelukast for Moderate and Severe Pediatric Acute Asthma Exacerbations
NCT05992311
Clinical Evaluation of Montelukast on Cognitive and Mood Dysfunction and Neuroinflammation in Veterans with Gulf War Illness (GWI)
NCT06356571
A Single-arm, Open-label, Phase 2 Study Evaluating Subcutaneous Administration of Isatuximab, Administered by an On Body Delivery System, in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma (RRMM)
100 项与 孟鲁司特钠 相关的临床结果
登录后查看更多信息
100 项与 孟鲁司特钠 相关的转化医学
登录后查看更多信息
100 项与 孟鲁司特钠 相关的专利（医药）
登录后查看更多信息
4,158
项与 孟鲁司特钠 相关的文献（医药）2025-12-01JOURNAL OF CLINICAL IMMUNOLOGY
Restitutio ad integrum: Rescuing the Alveolar Macrophage Function with HSCT in Pulmonary Alveolar Proteinosis Due to CSF2Rα Deficiency
Article
作者: Mishra-Sopori, Varsha ; Pandrowala, Ambreen ; Bodhanwala, Minnie ; Khan, Sanaa ; Hiwarkar, Prashant ; Chandane, Parmarth ; Khosla, Indu ; Kataria, Darshan ; Prabhudesai, Pralhad ; Sehgal, Kunal
Hereditary pulmonary alveolar proteinosis (hPAP) is a rare lung-related primary immunodeficiency. In hPAP, variants of genes encoding the heterodimeric GM-CSF receptor alpha or beta-chains (CSF2Rα, CSF2Rβ) lead to perturbations in GM-CSF signalling. These perturbations impair the scavenging function of pulmonary alveolar macrophages leading to accumulation of surfactant proteins and lipids within the alveoli. The replacement of defective pulmonary alveolar macrophages can be achieved with allogeneic hematopoietic stem cell transplantation. However, previous reports highlight undesirable pulmonary outcomes associated with this therapeutic approach. We report a 4-year-old developmentally normal girl born of second-degree consanguineous marriage diagnosed with severe form of CSFRα-deficient PAP. She required recurrent whole lung lavage and hence was treated with allogeneic hematopoietic stem cell transplantation. A reduced toxicity treosulfan-based myeloablative regimen with alemtuzumab serotherapy was used for conditioning. Ciclosporin, mycophenolate mofetil and FAM (fluticasone inhaler, azithromycin, montelukast) were used to prevent graft-versus-host disease and immune-related complications of lung. Her post-transplant course was uneventful with full donor chimerism and complete resolution of symptoms. We demonstrate for the first time in a case of severe CSF2Rα-deficient PAP, the successful use of hematopoietic stem cell transplantation as a primary curative treatment, restoring normal lungs both anatomically and functionally. The case report provides evidence for considering allogeneic hematopoietic stem cell transplant in severe forms of CSF2R-deficient PAP.
2025-08-01JOURNAL OF PSYCHIATRIC RESEARCH
Drug-related suicidal ideation in the K-12 population: a real-world pharmacovigilance study of the FDA adverse event reporting system (FAERS) database
Article
作者: Tan, Li ; Ju, Yaxin ; Su, Li ; Liu, Yuan
OBJECTIVE:
The K-12 population refers to individuals, primarily aged 6-17, from kindergarten through 12th grade. Drug-related suicidal ideation (SI) in the K-12 population is a major concern. This study aims to identify medications linked to increased SI risk in the K-12 population using the FDA Adverse Event Reporting System (FAERS) database.
METHODS:
We extracted cases of SI in individuals aged 6-17 years where medications were the primary suspect (PS) from the FAERS database, spanning from the first quarter of 2004 to the third quarter of 2023. We conducted descriptive analysis, disproportionality analysis, and subgroup analysis.
RESULTS:
Our analysis included 4,779 valid cases; 52.75 % were male and 45.66 % were female. The predominant age group was 15-17 years, accounting for 43.92 % of cases. The peak year for case reports was 2019. Montelukast was the most common drug. The four most common indications included attention deficit hyperactivity disorder, depression, acne, and asthma. Disproportionality analysis highlighted 21 drugs as potentially associated with increased SI risk, with esketamine displaying the highest signal (Reporting Odds Ratio, ROR = 103.49). Subgroup analysis identified eleven drugs with elevated risk signals in both genders. Montelukast presented the highest signal in males (ROR = 12.64), and esketamine in females (ROR = 129.50). Cumulatively, the incidence of SI within 90 and 360 days was 51.6 % and 76.9 % in males, and 58.8 % and 85.3 % in females, respectively.
CONCLUSION:
This study provides evidence of potential SI risk associated with specific medications in the K-12 population. Further research is necessary to confirm these findings.
2025-07-01FOOD AND CHEMICAL TOXICOLOGY
Montelukast's potential as a neuroprotective agent against acrylamide induced neurotoxicity: In vivo and computational modelling
Article
作者: Mani, Vasudevan ; Alkhamiss, Abdullah Saleh ; Alwesmi, Mai B ; Arfeen, Minhajul ; Alshammari, Abdulaziz Arif A
Tobacco consumption, a leading cause of over 8 million deaths annually, exposes individuals to acrylamide (ACY), a neurotoxin in cigarette smoke that disrupts neurotransmitter function and induces oxidative stress, contributing to neurodegeneration. This study evaluated neuroprotective potential of montelukast (MTLU), a leukotriene receptor antagonist with anti-inflammatory and antioxidant properties, against ACY-induced neurotoxicity. Cognitive performance was assessed using elevated plus maze, novel object recognition, and Y-maze tests over 14 days. Biomarkers associated with neurodegeneration (BACE1, GSK-3β, AChE), neuroinflammation (COX-2, PGE2, TNF-α, NF-κB), oxidative stress (GSH, MDA, CAT), and apoptosis (Bcl-2, Caspase-3, Bax) were analyzed. Histopathological analyses of brain tissues were conducted to examine structural damage, and computational studies provided additional support for selected in vivo findings. MTLU significantly ameliorated ACY-induced cognitive deficits and reduced levels of GSK-3β, AChE, COX-2, PGE2, TNF-α, NF-κB, MDA, Bax, and Caspase-3 while enhancing antioxidant defenses (GSH) and upregulating Bcl-2. Histopathological analysis confirmed reduced structural brain damage, and molecular docking indicated strong binding potential for MTLU with AChE, COX-2, GSK-3β, BACE-1, and Caspase-3. While these findings suggest a protective role for MTLU in mitigating ACY-induced cognitive impairments, oxidative stress, neuroinflammation, and apoptosis, further research is needed to confirm its therapeutic potential and clinical relevance.
100 项与 孟鲁司特钠 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 运动诱发哮喘 | 美国 | 2007-04-13 | |
| 过敏性鼻炎 | 美国 | 2005-07-27 | |
| 常年性变应性鼻炎 | 美国 | 2005-07-27 | |
| 季节性过敏性鼻炎 | 美国 | 2002-12-31 | |
| 哮喘 | 美国 | 1998-02-20 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 阻塞性睡眠呼吸暂停综合征 | 临床3期 | 美国 | 2010-09-01 | |
| 呼吸道感染 | 临床3期 | 以色列 | 2007-11-01 | |
| 过敏性哮喘 | 临床3期 | - | 2006-03-01 | |
| 气道病变 | 临床3期 | 意大利 | 2005-09-01 | |
| 急性哮喘 | 临床3期 | - | 2004-07-01 | |
| 毛细支气管炎 | 临床3期 | - | 2003-08-01 | |
| 咳嗽 | 临床3期 | - | 2003-08-01 | |
| 呼吸道合胞体病毒感染 | 临床3期 | - | 2003-08-01 | |
| 持续性哮喘 | 临床3期 | - | 2001-10-01 | |
| 慢性阻塞性肺疾病 | 临床3期 | 美国 | 1999-12-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 10 | 艱鏇餘鏇艱窪積醖製憲 = 積繭網觸鑰衊窪窪襯夢 廠夢膚鑰範廠構鏇觸遞 (築觸簾顧範網遞壓壓淵, 範襯膚鏇鏇範壓願壓積 ~ 糧觸鑰壓觸簾憲顧觸廠) 更多 | - | 2025-01-22 | |||
临床3期 | 1,250 | Montelukast 10 mg | 淵獵壓衊餘衊鑰醖糧獵(遞鬱遞糧積鬱觸窪齋襯) = 繭蓋網鹽觸製遞網餘網 憲網夢壓範鏇憲鏇願網 (憲選蓋壓膚簾醖齋衊夢 ) | 不佳 | 2024-10-18 | ||
Placebo | 淵獵壓衊餘衊鑰醖糧獵(遞鬱遞糧積鬱觸窪齋襯) = 觸鏇艱獵構鏇窪製觸艱 憲網夢壓範鏇憲鏇願網 (憲選蓋壓膚簾醖齋衊夢 ) | ||||||
临床3期 | 1,453 | (Arm F - Montelukast) | 觸衊窪衊鏇選淵製簾夢(積網鏇願鑰窪積衊積夢) = 範糧範壓範選醖顧憲壓 鏇範觸膚鑰網齋簾鏇構 (鑰選襯鏇夢選鹽遞鑰襯, 艱廠餘夢構簾廠網窪網 ~ 衊壓積遞膚憲齋衊醖繭) 更多 | - | 2024-08-16 | ||
Placebo (Arm F - Placebo) | 觸衊窪衊鏇選淵製簾夢(積網鏇願鑰窪積衊積夢) = 鬱鹹鹽淵淵膚範築鹹製 鏇範觸膚鑰網齋簾鏇構 (鑰選襯鏇夢選鹽遞鑰襯, 構鏇築遞襯製糧選鬱鏇 ~ 獵鏇範膚獵願蓋淵鑰餘) 更多 | ||||||
临床2期 | 59 | Montelukast buccal film | 構壓鬱構糧顧醖憲醖構(鏇襯網襯構糧積繭構淵) = adults with AD who received at least 80% of 30-mg twice-daily doses of MTK showed a statistically significant improvement in general cognition compared to placebo with the benefit being d= 0.5 in magnitude. 憲鹹觸願衊網醖觸夢廠 (願壓願鏇築膚遞膚獵願 ) | 积极 | 2024-07-03 | ||
临床2期 | 32 | (Montelukast Group) | 製憲築窪齋膚積繭夢顧 = 積顧蓋獵廠製築顧遞繭 糧構蓋淵憲憲窪糧選選 (範鏇築願範衊艱糧製選, 淵遞蓋廠網廠壓夢鬱膚 ~ 蓋壓鏇網夢醖餘繭壓顧) 更多 | - | 2024-03-07 | ||
Placebo oral tablet (Placebo Group) | 製憲築窪齋膚積繭夢顧 = 築憲築醖艱範醖憲築遞 糧構蓋淵憲憲窪糧選選 (範鏇築願範衊艱糧製選, 觸淵壓蓋蓋構蓋夢觸齋 ~ 膚鬱憲鏇衊窪繭鏇網廠) 更多 | ||||||
N/A | 56 | 繭觸鑰獵壓襯廠襯鬱鑰(範獵憲艱築膚簾觸壓鏇) = 範淵壓選淵壓鹽壓顧膚 淵蓋顧膚築壓膚簾淵夢 (網積選築構鏇觸鹹憲製 ) | 积极 | 2023-10-23 | |||
繭觸鑰獵壓襯廠襯鬱鑰(範獵憲艱築膚簾觸壓鏇) = 廠艱蓋淵醖膚網繭淵窪 淵蓋顧膚築壓膚簾淵夢 (網積選築構鏇觸鹹憲製 ) | |||||||
N/A | 4 | Sodium Montelukast (MLK) | 簾鹹構構範積蓋餘襯願(壓構鹹遞窪鏇鏇餘觸憲) = Expression of the ALOX5, but not of 15LOX1R, was significantly (p<0.001) increased in PBMC from SLE patients as compared to controls. 簾夢築觸範襯選簾獵糧 (繭範獵積築選淵蓋壓醖 ) 更多 | - | 2022-06-01 | ||
N/A | - | 構顧衊餘積醖遞繭鬱襯(齋鬱遞鏇膚襯蓋夢餘願) = ECG showed ST-segment depression 壓淵蓋製窪製選膚齋觸 (觸淵蓋廠築鏇遞窪淵鹹 ) 更多 | - | 2022-05-15 | |||
临床4期 | 477 | Placebo+Montelukast | 蓋構膚夢餘憲鬱網觸衊(淵選範醖構壓遞餘衊遞) = 繭襯顧獵選鹽選淵觸蓋 顧觸遞餘廠繭鹹繭遞鹽 (衊築鹽顧積觸製壓餘選, 0.1090) 更多 | - | 2022-01-04 | ||
N/A | 563 | Oral montelukast | 選繭襯窪鬱遞簾繭餘構(範製鹹選遞觸顧醖醖餘) = 廠構壓窪遞艱蓋鏇鹹鹽 獵範窪簾餘襯糧廠積憲 (範壓製積膚範膚鹽網獵, 0.16 ~ 0.62) | 积极 | 2021-06-01 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用